Glaxosmithkline | GSK - Operating Profit



Glaxosmithkline reported GBP2.44B in Operating Profit for its fiscal quarter ending in June of 2025.


Operating Profit Change Date
AbbVie USD 5.72B 1.98B Jun/2025
Amgen USD 2.66B 1.37B Jun/2025
AstraZeneca USD 3.51B 166M Jun/2025
Aurora Cannabis CAD -20220000 56.44M Jun/2025
Bausch Health Companies USD 457M 181M Jun/2025
Bristol-Myers Squibb USD 3.77B 366M Jun/2025
Canopy Growth CAD -22080000 1.74M Jun/2025
Corcept Therapeutics USD 26.67M 23.26M Jun/2025
Drreddys Laboratories INR 16.84B 1.88B Jun/2025
Eli Lilly USD 7.02B 1.61B Jun/2025
GlaxoSmithKline GBP 2.02B 193M Jun/2025
Glaxosmithkline GBP 2.44B 1.74B Jun/2025
J&J USD 6.94B 6.69B Jun/2025
Merck USD 6.36B 494M Jun/2025
Novartis USD 4.86B 201M Jun/2025
Pacira USD 10.23M 8.24M Jun/2025
Perrigo USD 55.6M 23.8M Jun/2025
Pfizer USD 2.6B 1.06B Jun/2025
Prestige Brands USD 71.76M 16.67M Jun/2025
Roche Holding CHF 4.39B 1.04B Dec/2024
Sanofi EUR 1.71B 573M Jun/2025
Supernus Pharmaceuticals USD 12.14M 14.74M Jun/2025
Takeda JPY 184.56B 259.5B Jun/2025
Teva Pharmaceutical Industries USD 899M 380M Jun/2025
Zoetis USD 1.02B 205M Jun/2025